Herbert Loong/immunooncologyindia.com
Jun 27, 2025, 07:22
Herbert Loong Shares Cost-Effectiveness Study on Lung Cancer Screening in Hong Kong
Herbert Loong, Chair-Elect of the International Affairs Committee and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO), shared a post on X:
“Happy to share with Lung Cancer community!
After 3+ years of work, we are pleased to share our cost effectiveness modelling for lung cancer screening in both high-risk populations determined by both smoking and non-smoking risk factors e.g. family history for an entire community.
Taking Hong Kong as an example of our East Asia region with specific lung cancer epidemiology and molecular characteristics, we have shown that ICER for high risk individuals based on factors not associated with smoking is even lower.
This is the first study of modelling for an entire health system catering for both high risk groups. This calls for government and other stakeholders to push forward territory wide lung cancer screening for ALL high risk individuals – regardless of smoking history.”
Title: Incorporating high-risk individuals beyond smoking history into lung cancer screening in Hong Kong: a cost-effectiveness study
Authors: Herbert Ho-fung Loong, Xuanqi Pan, Carlos K.H. Wong, Chao-Hua Chiu, Szu-Chun Yang, Matthew Shing Hin Chung, Molly Siu Ching Li, Lisa de Jong, Harry Groen, Maarten J. Postma, Pan-Chyr Yang
Read The Full Article at JTO Clinical and Research Reports.
More posts featuring Herbert Loong on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 13:14
Aug 8, 2025, 13:14
Aug 8, 2025, 13:11